Aromyx is a technology company.
Aromyx has raised $14.0M across 3 funding rounds.
Aromyx has raised $14.0M in total across 3 funding rounds.
Aromyx has raised $14.0M in total across 3 funding rounds.
Aromyx's investors include ClimacticVC, Mindset Ventures, Precursor Ventures, Rabo Ventures, Storm Ventures, Sure, TSVC Capital, Ulu Ventures, Zero Infinity Partners.
# Aromyx: Digitizing Human Sensory Perception
Aromyx is a biotechnology company that uses CRISPR-constructed biosensors and artificial intelligence to digitize and quantify the human senses of smell and taste.[1] Founded in 2014 and backed by Stanford StartX and DARPA, the company transforms subjective sensory experiences into objective, measurable data that enterprises can leverage for product development, quality control, and consumer targeting.[2][3]
The company serves a diverse customer base spanning pharmaceuticals, food and beverage, agriculture, and consumer goods—including over two dozen Fortune 500 companies across the U.S., Japan, China, and Europe.[3] Aromyx solves a fundamental problem: while humans can distinguish between a trillion different odors, we lack the ability to communicate these differences precisely and consistently.[4] By capturing the detection ability of human olfactory and taste receptors, Aromyx delivers quantitative sensory data that eliminates the need for animal testing and traditional consumer panels, dramatically accelerating product development cycles.[3]
The company is currently at the pre-Series A stage with approximately $500K in trailing twelve-month revenue and 14 employees.[1] It has demonstrated early traction through R&D partnerships with major pharmaceutical and agricultural companies, each valued at approximately $250,000.[1]
Aromyx was founded in May 2014 by a team with deep expertise spanning biotechnology, government research, and systems engineering.[1] The founding team includes executives with backgrounds at IBM, Seagate, and the Department of Defense, as well as Dr. Bill Harries, the company's Chief Scientist, who previously served as acting chief scientific officer of the Center for Structures of Membrane Proteins at UC San Francisco, where he developed advanced membrane protein expression and crystallization methods.[1] Another co-founder is an inventor of the biosensor technology itself and previously founded Target Discovery, a successful biotech firm.[1]
The core innovation emerged from recognizing a critical gap: while analytical chemistry can measure chemical compounds, it cannot replicate how the human brain perceives taste and smell. By leveraging CRISPR technology to construct proprietary biosensors that mimic human olfactory receptors, the team created a way to capture and digitize these subjective sensory experiences into objective data.[1][2] Early validation came through pilot programs with Fortune 500 companies in pharmaceuticals and agriculture, demonstrating commercial viability before pursuing Series A funding.
Aromyx operates at the intersection of three powerful trends: the digitization of traditionally analog domains, the rise of synthetic biology and CRISPR applications, and the growing demand for objective, data-driven product development in regulated industries.
The company is riding the wave of precision biotechnology, where CRISPR and other gene-editing tools enable entirely new categories of measurement and control. As regulatory scrutiny around animal testing intensifies and consumer preferences shift toward transparency, Aromyx's alternative approach gains strategic importance. In pharmaceuticals and food science, where product development cycles are measured in years and costs in hundreds of millions, even modest acceleration translates to significant competitive advantage.
Additionally, Aromyx addresses a gap in the AI and data economy: while companies have digitized vision, hearing, and touch through sensors and algorithms, smell and taste remained largely subjective and unmeasurable at scale. By converting these senses into quantifiable data, Aromyx unlocks new possibilities for personalization, quality assurance, and market segmentation—particularly valuable in e-commerce, where consumers cannot physically sample flavored or scented products before purchase.[3]
The company's Fortune 500 customer base and institutional backing across multiple geographies suggest that enterprises recognize the strategic value of sensory digitization, positioning Aromyx as a foundational technology provider rather than a niche player.
Aromyx stands at an inflection point. With demonstrated customer traction, a defensible technology moat, and a founding team with proven execution capability, the company is well-positioned for Series A funding and scaling. The next phase will likely involve deepening penetration in pharmaceutical and food science—where regulatory compliance and product optimization create durable demand—while exploring adjacent markets in diagnostics and sustainability.
The broader opportunity is substantial: as enterprises increasingly rely on data-driven decision-making, the ability to quantify sensory perception becomes a competitive necessity rather than a novelty. If Aromyx can establish itself as the standard platform for sensory digitization, it could evolve from a specialized biotech tool into essential infrastructure for product development across multiple industries. The timing is favorable—regulatory pressure against animal testing, advances in synthetic biology, and the maturation of AI for complex data interpretation all work in the company's favor.
Aromyx has raised $14.0M across 3 funding rounds. Most recently, it raised $10.0M Series A in July 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2021 | $10.0M Series A | ClimacticVC, Mindset Ventures, Precursor Ventures, Rabo Ventures, Storm Ventures, Sure, TSVC Capital, Ulu Ventures, Zero Infinity Partners | |
| Feb 1, 2017 | $3.0M Seed | ClimacticVC, Mindset Ventures, Precursor Ventures, Storm Ventures, Sure, Ulu Ventures, Zero Infinity Partners | |
| May 1, 2015 | $1.0M Seed | TSVC Capital |